Difficulties in establishing reference intervals for special fluids: The example of 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 7, 2004, Pages 833-841

  Dhondt, Jean Louis ^a  

^a Centre Hospitalier Saint Philibert GHICL   (France)

Author keywords

5 hydroxyindoleacetic acid; Cerebrospinal fluid; Homovanillic acid; Neurotransmitters; Reference values

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BRAIN MONOAMINE; HOMOVANILLIC ACID;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ADULT; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN METABOLISM; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONCENTRATION (PARAMETERS); DOWN SYNDROME; FEMALE; GROUPS BY AGE; HUMAN; INFECTION; LABORATORY TEST; MALE; MENTAL DISEASE; MONOAMINE METABOLISM; NEUROLOGIC DISEASE; PREMATURITY; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

BIOGENIC MONOAMINES; CEREBROSPINAL FLUID; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; LABORATORY TECHNIQUES AND PROCEDURES; OBSERVER VARIATION; REFERENCE VALUES;

EID: 4344606128     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.137     Document Type: Review

References (103)

1. Bräutigam C, Weykamp C, Hoffmann GF, Wavers RA. Neurotransmitter metabolites in CSF: an external quality control scheme. J Inherit Metab Dis 2002;25:287-98.
2. Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol 1992;262:R20-4.
3. Lups S, Haan AMFH. The cerebrospinal fluid. Elsevier: Amsterdam, 1954.
4. Johansson B, Roos BE. Concentrations of monoamine metabolites in human lumbar and cisternal cerebrospinal fluid. Acta Neurol Scand 1975;52:137-44.
5. Nordin C, Eklundh T, Fernstrom V, Swedin A, Zachau AC. Gradients of CSF monoamine metabolites: a comparison between male and female volunteers. J Psychiatr Res 1995;29:133-40.
6. Blennow K, Wallin A, Gottfries CG, Karlsson I, Mansson JE, Skoog I, et al. Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol 1993;3:55-61.
7. Blennow K, Wallin A, Gottfries CG, Mansson JE, Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm Park Dis Dement Sect 1993;5:5-15.
8. Nordin C, Lindstrom L, Wieselgren IM. Acid monoamine metabolites in the CSF of healthy controls punctured without preceding strict bedrest: a retrospective study. J Psychiatr Res 1996;30:127-33.
9. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: a review of methodology. Schizophrenia Bulletin 1992;18:123-48.
10. Emanuelsson BM, Widerlov E, Walleus H, Paalzow LK. Determinations of 5-hydroxyindoleacetic acid and homovanillic acid in human CSF with monitoring of probenacid levels in CSF and plasma. Psychopharmacology (Berl) 1987;92:144-9.
11. Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. Psychiatr Res 1986;20:175-93.
12. Komori H, Matsuishi T, Yamada S, Ichikawa K, Amamoto M, Yamashita F. Elevated biopterin and homovanillic acid levels in cerebrospinal fluid from children with aseptic meningitis. J Child Neurol 1994;9:22-5.
13. Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacol Rev 1980;32: 315-35.
14. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 1985;147:276-82.
15. Sofic E, Riederer P, Schmidt B, Fritze J, Kolleger H, Dierks T, et al. Biogenic amines and metabolites in CSF from patients with HIV infection. Biogenic Amines 1992;8:293-8.
16. Guttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 1986;9 Suppl 2:169-77.
17. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, et al. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 1997;247:297-302.
18. Seifert WE, Foxx JL, Butler IJ. Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid. Ann Neurol 1980;8:38-42.
19. Takeuchi Y, Matsushita H, Sakai H, Kawano H, Yoshimoto K, Sawada T. Developmental changes in cerebrospinal fluid concentrations of monoamine-related substances revealed with a Coulochem electrode array system. J Child Neurol 2000;15:267-70.
20. Riddle MA, Anderson GM, McIntosh S, Harcherik DF, Shaywitz BA, Cohen DJ. Cerebrospinal fluid monoamine precursor and metabolite levels in children treated for leukemia: age and sex effects and individual variability. Biol Psychiatry 1986;21:69-83.
21. Hyland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993;34:10-4.
22. Langlais PJ, Walsh FX, Levy HL. Cerebrospinal fluid neurotransmitter metabolites in neurologically normal infants and children. Pediatrics 1985;75:580-6.
23. Pinkerton CR, Smith I, Leeming RJ, Sarna G, Hyland K, Curzon G, et al. Biopterin and neurotransmitter amine metabolism in children with acute lymphoblastic leukemia receiving methotrexate therapy. J Pediatr 1986;108:470-4.
24. Hedner J, Lundell KH, Breese GR, Mueller RA, Hedner T. Developmental variations in CSF monoamine metabolites during childhood. Biol Neonate 1986;49:190-7.
25. Silverstein FS, Johnston MV, Hutchinson RJ, Edwards NL. Lesh-Nyhan syndrome: CSF neurotransmitter abnormalities. Neurology 1985;35:907-11.
26. Tohgi H, Takahashi S, Abe T. The effect of age on concentrations of monoamines, amino acids, and their related substances in the cerebrospinal fluid. J Neural Transm (Park Dis Dement Sect) 1993;5:215-26.
27. Gonzalez-Quevedo A, Garcia JC, Fernandez R, Fernandez Cartaya L. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system. Bol Estud Med Biol 1993;41:13-9.
28. Hartikainen P, Soininen H, Reinikainen KJ, Sirvio J, Soikkeli R, Riekkinen PJ. Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors. J Neural Transm Gen Sect 1991;84:103-17.
29. Hagenfeldt L, Bjerkenstedt L, Edman G, Sedvall G, Wiesel FA. Amino acids in plasma and CSF and monoamine metabolites in CSF: interrelationship in healthy subjects. J Neurochem 1984;42:833-7.
30. Eklundh T, Gunnarsson T, Nordin C. Monoamine compounds in cerebrospinal fluid of healthy subjects punctured without preceding strict bed rest: a pilot study. Neuropsychobiology 2001;43:5-10.
31. Furukawa Y, Nishi K, Kondo T, Tanabe K, Mizuno Y. Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci 1992; 111:65-72.
32. Strombom U, Krotkiewski M, Blennow K, Mansson JE, Ekman R, Bjorntorp P. The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution. Int J Obes Relat Metab Disord 1996;20:361-8.
33. Teff KL, Young SN, Blundell JE. The effect of protein or carbohydrate breakfasts on subsequent plasma amino acid levels, satiety and nutrient selection in normal males. Pharmacol Biochem Behav 1989;34:829-37.
34. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6.
35. Geracioti TD Jr, West SA, Baker DG, Hill KK, Ekhator NN, Wortman MD, et al. Low CSF concentration of a dopamine metabolite in tobacco smokers. Am J Psychiatry 1999;156:130-2.
36. Nicoletti F, Raffaele R, Falsaperla A, Paci R. Circadian variation in 5-hydroxyindoleacetic acid levels in human cerebrospinal fluid. Eur Neurol 1981;20:9-12.
37. Kirwin PD, Anderson GM, Chappell PB, Saberski L, Leckman JF, Geracioti TD, et al. Assessment of diurnal variation of cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in healthy human females. Life Sci 1997;60:899-907.
38. Ben Menachem E, Persson L, Schechter PJ, Haegele KD, Huebert N, Hardenberg J. Cerebrospinal fluid parameters in healthy volunteers during serial lumbar punctures. J Neurochem 1989;52:632-5.
39. Eriksson E, Alling C, Andersch B, Andersson K, Berggren U. Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome. Neuropsychopharmacology 1994;11:201-13.
40. Eklundh T, Fernstrom V, Nordin C. Influence of tapping-time and atmospheric pressure on concentrations of monoamine metabolites in the cerebrospinal fluid: a prospective study in female volunteers. J Psychiatr Res 1994;28:511-7.
41. Brewerton TD, Berrettini WH, Nurnberger JL, Linnoila M. Analysis of seasonal fluctuations of CSF monoamine metabolites and neuropeptides in normal controls: findings with 5-HIAA and HVA. Psychiatry Res 1988; 23:257-65.
42. Swedo SE, Kruesi MJP, Leonard HL. Lack of seasonal variation in pediatric lumbar cerebrospinal fluid neuro-transmitter metabolite concentration. Acta Psychiatr Scand 1989;80:644-9.
43. Chotai J, Asberg M. Variations in CSF monoamine metabolites according to the season of birth. Neuropsychobiology 1999;39:57-62.
44. Hill KK, West SA, Ekhator NN, Bruce AB, Wortman MD, Baker DG, et al. The effect of lumbar puncture stress on dopamine and serotonin metabolites in human cerebrospinal fluid. Neurosci Lett 1999;276:25-8.
45. Eklundh T, Nordin C. Intraspinal pressure influences CSF disposition of tryptophan and 5-hiaa. Neuropsychobiology 2001;44:84-7.
46. Nordin C, Swedin A, Zachau A. CSF 5-HIAA and atmospheric pressure. Biol Psychiatry 1992;31:644-5.
47. Silverstein FS, Donn S, Buchanan K, Johnston MV. Concentrations of homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid from human infants in the neonatal period. J Neurochem 1984;43:1769-72.
48. Dhondt JL, Forzy G. Etablissement de valeurs usuelles pour les acides 5-hydroxyindolacétique et homovanillique dans le liquide céphalorachidien. Ann Biol Clin (Paris) 2003;61:69-75.
49. Lopez-Ibor JJ Jr. Serotonin and psychiatric disorders. Int Clin Psychopharmacol 1992;7 Suppl 2:5-11.
50. Kovacs K, Bors L, Tothfalusi L, Jelencsik I, Bozsik G, Kerenyi L, et al. Cerebrospinal fluid (CSF) investigations in migraine. Cephalalgia 1989;9:53-7.
51. Hartikainen P, Reinikainen KJ, Soininen H, Sirviö J, Soikkeli R, Riekkinen PJ. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral slerosis and normal controls. J Neural Trasnm 1992;4:53-68.
52. Langlais PJ, Wardlow ML, Yamamoto H. Changes in CSF neurotransmitters in infantile spasms. Pediatr Neurol 1991;7:440-5.
53. Airaksinen E, Tuomisto L, Riikonen R. The concentrations of GABA, 5-HIAA and HVA in the cerebrospinal fluid of children with infantile spasms and the effects of ACTH treatment. Brain Dev 1992;14:386-90.
54. Furukawa Y, Mizuno Y, Nishi K, Narabayashi H. A clue to the pathogenesis of dopa-responsive dystonia. Ann Neurol 1995;37:139-40.
55. Nygaard TG, Wooten GF. Dopa-responsive dystonia: some pieces of the puzzle are still missing. Neurology 1998;50:853-5.
56. Millot F, Dhondt JL, Mazingue F, Mechinaud F, Ingrand P, Guilhot F. Changes of cerebral biopterin and biogenic amine metabolism in leukemic children receiving 5 g/m2 intravenous methotrexate. Pediatr Res 1995;37: 151-4.
57. Stahl SM, Faull KF, Berger PA. CSF monoamine metabolites in movement disorders and normal aging. Arch Neurol 1985;42:166-9.
58. Trouillas P, Charles N, Renaud B, Eynard N, Adeleine P. Serotonergic CSF abnormalities in human acquired and genetic ataxias. In: Trouillas P, Fuxe K. editors. Serotonin: the cerebellum, and ataxia. New York: Raven Press, 1993:311-22.
59. Laxer KD, Sourkes TL, Fang TY, Young SN, Gauthier SG, Missala K. Monoamine metabolites in the CSF of epileptic patients. Neurology 1979;29:1157-61.
60. Devinsky O, Emoto S, Goldstein DS, Stull R, Porter RJ, Theodore WH, et al. Cerebrospinal fluid and serum levels of dopa, catechols, and monoamine metabolites in patients with epilepsy. Epilepsia 1992;33:263-70.
61. Habel A, Yates CM, McQueen JK, Blackwood D, Elton RA. Homovanillic acid and 5-hydroxyindoleacetic acid in lumbar cerebrospinal fluid in children with afebrile and febrile convulsions. Neurology 1981;31:488-91.
62. Laxer KD, Sourkes TL, Fang TY, Young SN, Gauthier SG, Missala K. Monoamine metabolites in the CSF of epileptic patients. Neurology 1979;29:1157-61.
63. Andersen O, Johansson B, Svennerholm L. Monoamine metabolites in successive samples of spinal fluid. A comparison between healthy volunteers and patients with multiple sclerosis. Acta Neurol Scand 1981;63: 247-54.
64. Corona GL, Cucchi ML, Frattini P, Santagostino G, Schinelli S, Romani A, et al. Monoamine metabolites in biological fluids of multiple sclerosis patients. Biogenic Amines 1991;8:127-33.
65. Wallin A, Blennow K, Edman A, Mansson JE. Decreased lumbar cerebrospinal fluid levels of monoamine metabolites in vascular dementia. Int Psychogeriatr 1996; 8:425-36.
66. Tohgi H, Ueno M, Abe T, Takahashi S, Nozaki Y. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J Neural Transm 1992;4:69-77.
67. Smirne S, Franceschi M, Truci G, Camerlingo M, Pirola R, Ferini-Strambi L, et al. Homovanillic acid and 5-hydroxyindoleacetic acid modifications in CSF of patients with stroke and multi-infarct dementia. Stroke 1985;16:1003-6.
68. Mena MA, Aguado EG, de Yebenes JG. Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. Acta Neurol Scand 1984;69:218-25.
69. Roy A, Karoum F, Pollack S. Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 1992;49:447-50.
70. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32.
71. Roy A, Pickar D, Linnoila M, Doran AR, Ninan P, Paul SM. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res 1985;15:281-92.
72. Engstrom G, Alling C, Blennow K, Regnell G, Traskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol 1999;9:399-405.
73. Westenberg HG, Verhoeven WM. CSF monoamine metabolites in patients and controls: support for a bimodal distribution in major affective disorders. Acta Psychiatr Scand 1988;78:541-9.
74. Houvenagel E, Forzy G, Leloire O, Gallois P, Hary S, Hautecoeur P, et al. Monoamines du liquides céphalo-rachidien dans la fibromyalgie primitive. Rev Rhumat 1990;57:21-3.
75. Almay BG, Haggendal J, von Knorring L, Oreland L. 5-HIAA and HVA in CSF in patients with idiopathic pain disorders. Biol Psychiatry 1987;22:403-12.
76. France RD, Urban BJ, Pelton S, Kilts CD, Hong JS, Nemeroff CB. CSF monoamine metabolites in chronic pain. Pain 1987;31:189-98.
77. Hsiao JK, Colison J, Bartko JJ, Doran AR, Konicki PE, Potter WZ, et al. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1993;50:606-14.
78. Miller C, Kirchmair R, Troger J, Saria A, Fleischhacker WW, Fischer-Colbrie R, et al. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol Psychiatry 1996;39:911-8.
79. Backman J, Alling C, Alsen M, Regnell G, Traskman-Bendz L. Changes of cerebrospinal fluid monoamine metabolites during long-term antidepressant treatment. Eur Neuropsychopharmacol 2000;10:341-9.
80. Jacobsen LK, Frazier JA, Malhotra AK, Karoum F, McKenna K, Gordon CT, et al. Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Am J Psychiatry 1997;154:69-74.
81. Blennow K, Wallin A, Gottfries CG, Lekman A, Karlsson I, Skoog I, et al. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 1992;13:107-13.
82. Parnetti L, Gaiti A, Reboldi GP, Santucci C, Mecocci P, Brunetti M, et al. CSF monoamine metabolites in old age dementias. Mol Chem Neuropathol 1992;16:143-57.
83. Anderson GM. Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder. Med Biol 1987;65:67-74.
84. Narayan M, Srinath S, Anderson GM, Meundi DB. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry 1993;33:630-5.
85. Reimherr FW, Wender PH, Ebert MH, Wood DR. Cerebrospinal fluid homovanillic acid and 5-hydroxyindoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Res 1984;11:71-8.
86. Brewerton TD. Toward a unified theory of serptonin dysregulation in eating and related disorders. Psychoneuroendocrinology 1995;20:561-90.
87. Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry 1994;51:20-7.
88. Goldman D, Dean M, Brown GL, Bolos AM, Tokola R, Virkkunen M, et al. D2 dopamine receptor genotype and cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxyphenylglycol in alcoholics in Finland and the United States. Acta Psychiatr Scand 1992;86:351-7.
89. Giroud M, Dumas R, Bralet J. 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid of children with febrile convulsions. Epilepsia 1990;31:178-81.
90. Silverstein FS, Hutchinson RJ, Johnston MV. Cerebrospinal fluid biogenic amine metabolites in children during treatment for acute lymphocytic leukemia. Pediatr Res 1986;20:285-91.
91. Kay AD, Schapiro MB, Riker AK, Haxby JV, Rapoport SI, Cutler NR. Cerebrospinal fluid monoamine metabolites are elevated in adults with Down's syndrome. Ann Neurol 1987;21:408-11.
92. Zoghbi HY, Percy AK, Riccardi VM. Reduction of biogenic amines levels in the Rett syndrome. N Engl J Med 1985;313:921-4.
93. Lekman A, Witt-Engerstrom I, Hagberg B. CSF and urine biogenic amine metabolites in Rett syndrome. Clin Genet 1990;37:173-8.
94. Dhondt JL. Tetrahydrobiopterin deficiencies: lessons from the compilation of 200 patients. Dev Brain Dysfunct 1993;6:141-57.
95. Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992; 42:1980-8.
96. Hyland K. The lumbar puncture for diagnosis of pediatric neurotransmitter diseases. Ann Neurol 2003;54 Suppl 6:S13-7.
97. Lamers KJ, Wevers RA. Abnormalities of biogenic amines affecting the metabolism of serotonin and catecholamines. Mult Scler 1998;4:37-8.
98. Burlina AB, Bonafé L, Ferrari V, Suppiej A, Zacchello F, Burlina AP. Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J Inherit Metab Dis 2000;23:313-6.
99. Hyyppa MT, Scheinin H, Alaranta H, Hurme M, Lahtela K, Scheinin M. Neurotransmission and the experience of low back pain; no association between CSF monoamine metabolites and pain. Pain 1985;21:57-65.
100. Brane G, Gottfries CG, Blennow K, Karlsson I, Lekman A, Parnetti L, et al. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. Alzheimer Dis Assoc Disord 1989;3:148-56.
101. Geracioti TD Jr, Keck PE Jr, Ekhator NN, West SA, Baker DG, Hill KK, et al. Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid. Biol Psychiatry 1998;44:228-33.
102. Hildebrand J, Mousse Z, Raftopoulos C, Vanhouche J, Laute MA, Przedborski S. Variations of homovanillic acid levels in ventricular cerebrospinal fluid. Acta Neurol Scand 1992;85:340-2.
103. Hildebrand J, Bourgeois F, Goldman S. Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid. Acta Neurol Scand 1990;81:427-30.